Evanston Advisors’s Gilead Sciences GILD Stock Holding History

Evanston Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-102,783	Closed	-$6.98M	–	69
2017 Q1	$6.98M	Buy	102,783 +24,190	+31%	+$1.7M	1.89%	33
2016 Q4	$5.63M	Buy	78,593 +2,464	+3%	+$183K	1.73%	35
2016 Q3	$6.02M	Buy	76,129 +7,342	+11%	+$596K	1.89%	30
2016 Q2	$5.74M	Buy	68,787 +4,686	+7%	+$416K	1.87%	26
2016 Q1	$5.89M	Buy	64,101 +3,230	+5%	+$291K	1.94%	29
2015 Q4	$6.16M	Buy	60,871 +1,238	+2%	+$129K	2.15%	23
2015 Q3	$5.86M	Buy	59,633 +1,812	+3%	+$201K	1.94%	25
2015 Q2	$6.77M	Buy	57,821 +678	+1%	+$74.1K	2.22%	7
2015 Q1	$5.61M	Buy	57,143 +54,928	+2,480%	+$5.58M	1.84%	34
2014 Q4	$209K	Hold	2,215	–	–	0.07%	61
2014 Q3	$236K	Buy	+2,215	New	+$217K	0.08%	62

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Evanston Advisors's GILD Position: Q2 2017 in Review

Evanston Advisors sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 102,783 shares — an estimated $6.98M sold.

Evanston Advisors first reported a position in GILD in Q3 2014 and held it in 11 quarters. The position peaked at $6.98M in Q1 2017. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

Evanston Advisors reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
Evanston Advisors sold 102,783 Gilead Sciences shares in Q2 2017, an estimated $6.98M.
Evanston Advisors first reported a position in Gilead Sciences in Q3 2014 and held it in 11 quarters.
Evanston Advisors's Gilead Sciences position peaked at $6.98M in Q1 2017.
1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Evanston Advisors's 13F filing for Q2 2017, filed 9 Aug 2017.